Evaluating Adverse Reactions and Perceived Advantages of Pharmacotherapy in Pediatric Patients with Chronic Non-Cancer Pain - Top-Institutions - MDSpire

Evaluating Adverse Reactions and Perceived Advantages of Pharmacotherapy in Pediatric Patients with Chronic Non-Cancer Pain

  • By

  • Kacper Niburski

  • Nada Mohamed

  • Dominique Dundaru-Bandi

  • Victor Hugo Gonzalez Cardenas

  • Marie Vigouroux

  • Rebecca Pitt

  • Pablo Ingelmo

  • April 20, 2026

  • 0 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    Boston Children's Hospital
    Boston Children's Hospital

    Boston, MA

    Key Differentiators

    • Pediatric Pain Medicine
    • Pediatric Neurology
    • Clinical Pharmacology

  • #2

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Pain Management
    • Pediatric Pharmacology
    • Pediatric Psychology

  • #3

    Seattle Children's Hospital
    Seattle Children's Hospital

    Seattle, WA

    Key Differentiators

    • Pediatric Pain Medicine
    • Pharmacology
    • Pediatric Rheumatology

  • #4

    Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical Center

    Cincinnati, OH

    Key Differentiators

    • Pediatric Pain Management
    • Clinical Pharmacology
    • Pediatric Neurology

  • #5

    Johns Hopkins Children's Center
    Johns Hopkins Children's Center

    Baltimore, MD

    Key Differentiators

    • Pediatric Pain Medicine
    • Pharmacology
    • Pediatric Psychiatry

Original Source(s)

Evaluating Adverse Reactions and Perceived Advantages of Pharmacotherapy in Pediatric Patients with Chronic Non-Cancer Pain

  • by Kacper Niburski, Nada Mohamed, Dominique Dundaru-Bandi, Victor Hugo Gonzalez Cardenas, Marie Vigouroux, Rebecca Pitt, Pablo Ingelmo

  • April 20, 2026

Related Content

Secular trends in HbA1c levels among children and adolescents with type 1 diabetes

Gene Therapy Reaches XLRS Milestone

Atsena Therapeutics reports positive interim data for XLRS gene therapy

  • May 25, 2026

  • 3 min
Ultrasound omental fat as a precocious marker of metabolic adiposity in children